Inocucor develops and sells biological crop stimulants using a patented fermentation process, with two commercial products: Synergro (a live-cell formulation for high-value produce) and Synergro Free (a cell-free bio-fertilizer for commodity row crops). The Montreal-headquartered company combines multi-strain bacteria and yeasts into products intended to boost plant growth via metabolic signals rather than live microbes. Inocucor is pursuing geographic expansion in Brazil, Argentina, Uruguay and Western Europe (notably Spain) and is opening a Denver office to expand U.S. reach. The company has begun executing an acquisition-led growth strategy and completed its first acquisition of ATP Nutrition to combine R&D and distribution capabilities. Inocucor plans to create product combinations of biologicals and crop nutrition tailored by plant type, geography and soil conditions to improve efficacy. Financially, Inocucor closed a final Series B on $54.4 million and its commercialized products and grower sales were cited by investors as differentiators in the biologicals space. Inocucor develops and produces biological crop inputs for high-value produce and row crops, using a patented fermentation process to combine multi-strains of bacteria, yeasts and fungi into biostimulants. Its first- and second-generation products, Synergro® and Synergro Free™, are designed to improve yields, shorten growing periods and create resilient soils for farmers and greenhouse growers. The company is also advancing a suite of microbial biocontrol products targeting economically devastating diseases in potatoes, tomatoes and strawberries. Proceeds from the Series B will be used to accelerate commercialization through increased production and marketing of current products and to advance biocontrol development. Inocucor operates an R&D-focused Technical Center of Excellence in Montreal that is being expanded from 10,000 to 20,000 square feet and is constructing a 30,000-square-foot U.S. headquarters and commercialization office in Centennial, Colorado. The company employs about 40 people across Montreal and the U.S. and anticipates adding another 25–30 high-level scientific and managerial professionals over the next year. The company is led by President and CEO Donald R. Marvin. Inocucor Technologies develops sustainable biological crop inputs using a patented fermentation process that combines multi-strains of bacteria and yeasts into soil and plant optimizers. Its flagship live-cell product, Garden Solution®, will be rebranded in the U.S. as Synergro™, and the company also offers Synergro Free™, a cell-free bio-fertilizer additive for commodity row crops. The product pipeline includes bio-control formulations targeting diseases in high-value crops such as strawberries, tomatoes and potatoes. Inocucor is starting internal and external field trials for the 2017 growing season based on prior row-crop trial data from commercial partners in Latin America and North America. The company plans to use new funding to open a U.S. headquarters and commercialization office, increase manufacturing capacity at its Montreal pilot production and R&D facility, and add managerial and scientific staff. The company is led by President and CEO Donald R. Marvin. Inocucor Technologies develops sustainable microbial crop accelerators, with its flagship product Garden Solution produced through fermentation akin to winemaking to boost soil microbial diversity and nutrient delivery. Garden Solution is approved for sale in 27 U.S. states and is in use by farmers and greenhouse growers in North Carolina, South Carolina, Florida, Georgia and Virginia. The company is led by president and CEO Donald R. Marvin. Inocucor’s growth strategy emphasizes establishing commercial partnerships and making strategic acquisitions to commercialize its proprietary microbial consortia technology and broaden its product pipeline. The company plans to expand large-scale field trials and commercialization activities in North and South America for second- and third-generation cell-free biological formulations, proprietary new biological entities and active compounds for bio-fertility and bio-protection. Financially, Inocucor recently raised additional capital via an extended Series A to support scale-up of its Garden Solution. Inocucor Technologies develops patented fermentation-based solutions and live-microbe products aimed at improving seed germination and increasing crop yields. Its first product, Garden Solution, employs live microbes to improve the phyto-microbiome and plant health. The company uses a fermentation process described as similar to winemaking to produce its solutions. Inocucor is launching a second-generation cell-free bio-stimulation product targeting the production agriculture market and plans to accelerate its commercialization. Management says proceeds from financing will be used to further commercialize its patented technology and may be used to acquire complementary technologies and products currently under review. The company is led by president and CEO Donald R. Marvin.

Total raised

$99M

Funding rounds

5

Latest round

Series B

Latest activity

Apr 2018